1. Home
  2. MSGY vs MAIA Comparison

MSGY vs MAIA Comparison

Compare MSGY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MSGY

Masonglory Limited Ordinary Shares

N/A

Current Price

$2.70

Market Cap

39.5M

Sector

N/A

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.43

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSGY
MAIA
Founded
2018
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
44.9M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
MSGY
MAIA
Price
$2.70
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
650.6K
1.0M
Earning Date
12-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$23,318,482.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.82
N/A
Revenue Growth
13.04
N/A
52 Week Low
$0.83
$0.87
52 Week High
$22.20
$2.74

Technical Indicators

Market Signals
Indicator
MSGY
MAIA
Relative Strength Index (RSI) N/A 56.09
Support Level N/A $1.13
Resistance Level N/A $1.75
Average True Range (ATR) 0.00 0.17
MACD 0.00 0.02
Stochastic Oscillator 0.00 47.58

Price Performance

Historical Comparison
MSGY
MAIA

About MSGY Masonglory Limited Ordinary Shares

Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: